NTLA Q4 2019 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+38.8% YoY

Gross Profit

-$21M-190.2% margin

Operating Income

-$30M-272.2% margin

Net Income

-$28M-258.6% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

+3.0%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$334M

Total Liabilities

$64M

Stockholders' Equity

$270M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$8M	+38.8%
Gross Profit	-$21M	-$12M	-72.7%
Operating Income	-$30M	-$21M	-43.5%
Net Income	-$28M	-$19M	-48.3%